

Leisha A Emens

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6077587/leisha-a-emens-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103
papers

8,502
citations

39
h-index

92
g-index

115
ext. papers

11,309
ext. citations

6.7
avg, IF

6.69
L-index

#	Paper	IF	Citations
103	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2108-2121	59.2	1871
102	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 44-59	21.7	422
101	The interplay of immunotherapy and chemotherapy: harnessing potential synergies. <i>Cancer Immunology Research</i> , 2015 , 3, 436-43	12.5	416
100	Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. <i>Journal of Experimental Medicine</i> , 2005 , 201, 1591-602	16.6	369
99	Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 671-686	4.4	345
98	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. <i>JAMA Oncology</i> , 2019 , 5, 74-82	13.4	326
97	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. <i>European Journal of Cancer</i> , 2017 , 81, 116-129	7.5	314
96	Breast Cancer Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018 , 24, 511-520	12.9	271
95	Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. <i>Clinical Cancer Research</i> , 2012 , 18, 3462-9	12.9	259
94	Targeting adenosine for cancer immunotherapy 2018 , 6, 57		228
93	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. <i>Human Pathology</i> , 2016 , 47, 52-63	3.7	214
92	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015 , 42, 587-600	5.5	206
91	Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5660-9	2.2	184
90	Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5911-8	2.2	178
89	A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. <i>Clinical Cancer Research</i> , 2007 , 13, 3951-9	12.9	169
88	Chemoimmunotherapy: reengineering tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 203-16	7.4	162
87	Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. <i>Cancer Research</i> , 2005 , 65, 8059-64	16.1	152

86	Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. <i>Cellular Immunology</i> , 2010 , 263, 79-87	4.4	100
85	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 3220-3228	12.9	99
84	The immune microenvironment of breast ductal carcinoma in situ. <i>Modern Pathology</i> , 2016 , 29, 249-58	9.8	98
83	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , 2020 , 10, 40-53	24.4	98
82	Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1597-611	3.5	94
81	OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. <i>Journal of Immunology</i> , 2006 , 176, 974-83	5.3	94
80	A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. <i>Cancer Immunology Research</i> , 2017 , 5, 468-479	12.5	87
79	Chemoimmunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2010 , 16, 295-303	2.2	87
78	HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. <i>Journal of Immunology</i> , 2003 , 171, 2161-9	5.3	87
77	Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. <i>Human Pathology</i> , 2013 , 44, 2055-63	3.7	76
76	Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. <i>American Journal of Therapeutics</i> , 2005 , 12, 243-53	1	71
75	Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1700-11	15.9	70
74	The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE ₂ in murine macrophages. <i>International Immunopharmacology</i> , 2010 , 10, 1220-8	5.8	67
73	Immune targeting in breast cancer. <i>Oncology</i> , 2015 , 29, 375-85	1.8	67
72	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology</i> , 2020 , 21, 1283-1295	21.7	62
71	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1005-1016	9.7	56
70	Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. <i>Gynecologic Oncology</i> , 2019 , 154, 314-322	4.9	54
69	A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. <i>Cancer Immunology Research</i> , 2014 , 2, 949-61	12.5	51

68	A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 915-24	4.4	50
67	The follow-up of breast cancer. <i>Seminars in Oncology</i> , 2003 , 30, 338-48	5.5	48
66	Cancer vaccines: on the threshold of success. <i>Expert Opinion on Emerging Drugs</i> , 2008 , 13, 295-308	3.7	47
65	GM-CSF-secreting vaccines for solid tumors: moving forward. <i>Discovery Medicine</i> , 2010 , 10, 52-60	2.5	40
64	Chemotherapy and tumor immunity: an unexpected collaboration. <i>Frontiers in Bioscience - Landmark</i> , 2008 , 13, 249-57	2.8	38
63	Targeting the programmed cell death-1 pathway in breast and ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2016 , 28, 142-7	2.4	35
62	First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. <i>Annals of Oncology</i> , 2021 , 32, 983-993	10.3	35
61	Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. <i>Human Gene Therapy</i> , 2018 , 29, 614-625	4.8	34
60	A new twist on autologous cancer vaccines. <i>Cancer Biology and Therapy</i> , 2003 , 2, 161-3	4.6	34
59	Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5585-5585	2.2	34
58	A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. <i>Human Gene Therapy</i> , 2004 , 15, 313-37	4.8	32
57	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. <i>Modern Pathology</i> , 2017 , 30, 1551-1560	9.8	30
56	Development of [F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. <i>Molecular Imaging</i> , 2019 , 18, 1536-1542	12.1	29
55	Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. <i>Human Pathology</i> , 2018 , 74, 135-147	3.7	28
54	Roadmap to a better therapeutic tumor vaccine. <i>International Reviews of Immunology</i> , 2006 , 25, 415-43	4.6	28
53	Cancer immunotherapy trials: leading a paradigm shift in drug development 2016 , 4, 42		28
52	Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. <i>Cancer</i> , 2018 , 124, 1904-1911	6.4	25
51	Specific immunotherapy in ovarian cancer: a systematic review. <i>Immunotherapy</i> , 2016 , 8, 1193-204	3.8	22

50	Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101947	14.4	21
49	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	21
48	Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. <i>Cancer Prevention Research</i> , 2011 , 4, 1993-2001	3.2	20
47	Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. <i>International Immunopharmacology</i> , 2017 , 46, 112-123	5.8	18
46	Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. <i>Breast Disease</i> , 2004 , 20, 13-24	1.6	18
45	Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab 2019 , 7, 274		17
44	GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. <i>Current Opinion in Molecular Therapeutics</i> , 2007 , 9, 490-7		17
43	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 153-62	4.4	15
42	Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. <i>Clinical Breast Cancer</i> , 2010 , 10, 40-5	3	15
41	Emerging immunotherapies in ovarian cancer. <i>Discovery Medicine</i> , 2015 , 20, 97-109	2.5	15
40	Cancer vaccines: an old idea comes of age. <i>Cancer Biology and Therapy</i> , 2003 , 2, S161-8	4.6	14
39	Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2816-22	2.2	13
38	The evolving management of metastatic triple negative breast cancer. <i>Seminars in Oncology</i> , 2020 , 47, 229-237	5.5	12
37	Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer. <i>Frontiers in Physiology</i> , 2020 , 11, 583333	4.6	12
36	Cancer vaccines in combination with multimodality therapy. <i>Cancer Treatment and Research</i> , 2005 , 123, 227-45	3.5	12
35	GM-CSF-secreting vaccines for solid tumors. <i>Current Opinion in Investigational Drugs</i> , 2009 , 10, 1315-24		11
34	Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis. <i>JAMA Ophthalmology</i> , 2019 , 137, 96-100	3.9	10
33	Immunotherapy in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021 , 27, 59-66	2.2	10

32	To Live or Not to Live—WHAT Depends on GAGE?. <i>Cancer Biology and Therapy</i> , 2002 , 1, 387-389	4.6	8
31	Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS1115-TPS1115	2.2	8
30	Toward a breast cancer vaccine: work in progress. <i>Oncology</i> , 2003 , 17, 1200-11; discussion 1214, 1217-8	1.8	8
29	Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 939-47	6.7	7
28	Invasive Lobular Carcinoma of the Male Breast: A Rare Histology in an Uncommon Disease. <i>Breast Care</i> , 2009 , 4, 36-38	2.4	7
27	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer 2021 , 9,		7
26	Re-purposing cancer therapeutics for breast cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 1299-305	7.4	6
25	It's TIME for a biomarker-driven approach to cancer immunotherapy 2016 , 4, 43		5
24	Current and emerging biologic therapies for triple negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2020 , 1-12	5.4	5
23	Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. <i>Clinical Breast Cancer</i> , 2021 , 21, 539-551	3	4
22	Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States \$35 Million/y. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 1090-9	6.7	4
21	Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer 2021 , 9,		4
20	Towards a therapeutic breast cancer vaccine: the next steps. <i>Expert Review of Vaccines</i> , 2005 , 4, 831-41	5.2	3
19	Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies. <i>Breast Cancer Research and Treatment</i> , 2021 , 1	4.4	3
18	The dawn of immunotherapy for breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2019 , 17, 332-335	0.6	3
17	New findings about endocrine therapy for breast cancer. <i>Breast</i> , 2003 , 12, 368-72	3.6	2
16	Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen. <i>OncolImmunology</i> , 2020 , 9, 1809926	7.2	2
15	Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. <i>JAMA Network Open</i> , 2021 , 4, e216322	10.4	2

14	Chemotherapy--A Viable Partner for Cancer Immunotherapy?. <i>JAMA Oncology</i> , 2015 , 1, 1095-7	13.4	1
13	Cancer Vaccines: An Old Idea Comes of Age. <i>Cancer Biology and Therapy</i> , 2003 , 2, 160-167	4.6	1
12	A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2002 , 76, 145-56	4.4	1
11	317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors 2020 , 8, A343-A343		1
10	Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	1
9	A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.. <i>Surgical Pathology Clinics</i> , 2022 , 15, 105-120	3.9	0
8	Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC). <i>Cancer Research</i> , 2022 , 82, GS2-10-GS2-10	10.1	0
7	Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry. <i>Methods in Enzymology</i> , 2020 , 631, 1-20	1.7	
6	A Novel Approach to Journal Club Designed to Immerse Trainees in a Peer-Review Process to Critically Evaluate Oncology Manuscripts. <i>Medical Science Educator</i> , 2016 , 26, 273-274	0.7	
5	Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer 2015 , 3, 49		
4	Jump-Starting Tumor Immunity with Breast Cancer Therapeutics 2007 , 169-187		
3	Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS1111-TPS1111		2.2
2	Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice. <i>Current Oncology</i> , 2021 , 28, 2741-2752	2.8	
1	Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab. <i>Cancer Research</i> , 2022 , 82, OT1-12-02-OT1-12-02	10.1	